EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Sofiva Genomics Co.,Ltd. (6615) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Sofiva Genomics Co.,Ltd. TWD 9.26, price TWD 34.00, upside -72.8%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW

SG Broad data Sep 24, 2026

Sofiva Genomics Co.,Ltd.

6615 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 9.26 TWD · Strongly overvalued (−73%)
!Quality 49/100
!Weak Growth (revenue 3y −8.0 %/yr)
!Thin margins · 3.8% net margin (TTM)
✓generates free cash flow
!Trails peers (5/13)
!Narrow moat 23/100
!Weak on past: 9 out of 100
!Weak on dividend: 17 out of 100
Watch Sofiva Genomics Co.,Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

81.68 TWD 29.20 TWD Fair Value 9.26 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 29.20 TWD – 81.68 TWD · fair‑value band 7.91 TWD – 10.58 TWD · the 34.00 TWD price screens above the 9.26 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Sofiva Genomics Co. in your weekly email

Every Wednesday you see whether Sofiva Genomics Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally.

Show more

Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessment for early/late-onset preeclampsia, folate metabolism genetic testing, congenital infection screening,carrier scan, thalassemia genetic testing, spinal muscular atrophy genetic testing, and fragile X syndrome genetic testing. It also provides baby genetic testing comprising sensorineural hearing loss genetic testing; congenital central hypoventilation syndrome genetic testing (CCHS); and congenital cytomegalovirus infection testing (CMV). In addition, the company offers cancer screening services, which includes human papillomavirus screening (HPV); and hereditary cancer testing services. Further, it develops precision medicine genetic testing; and offers testing services to patients and carriers with rare disorders. Sofiva Genomics Co.,Ltd. was founded in 2012 and is based in Taipei, Taiwan.

Stock analysis

Sofiva Genomics Co.,Ltd. (6615) currently trades at 34.00 TWD, while our model-based Fair Value estimate is 9.26 TWD, implying the stock looks roughly 267.1% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 19.49 TWD per share, and 0 of the 13 models we run sit above the 34.00 TWD price.

Bear case: the Dividend Discount group reads lowest at 2.87 TWD, and 13 of the 13 models stay below the price. Evidence for this calculation is high.

Scenario range: 7.91 TWD (bear) to 10.58 TWD (bull), the price of 34.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Sofiva Genomics Co.,Ltd. reported revenue of 386M TWD in FY2025 versus 508M TWD in FY2021, a compound −6.7%/yr. Reported net income was −9.4M TWD in FY2025.

Key figures

Market cap 734M TWD (≈ $23.1M) · P/E ratio 51.5 · P/S ratio 1.96 · EPS (TTM) 0.6600 TWD · Dividend yield 0.9% · Net margin −2.4% · Return on equity 2.3% · Return on assets (EBIT) −0.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 16% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −73%, 6615 screens richer than that median.

Fair Value models

Bear 7.91 TWD Fair Value 9.26 TWD Bull 10.58 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.4846 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 7.57 TWD 8.81 TWD 11.02 TWD 77
Growth DCF 7.71 TWD 8.90 TWD 10.88 TWD 74
Owner Earnings 14.82 TWD 18.70 TWD 25.67 TWD 72
All 13 models by family
DCF Models
FCF DCF 7.57 TWD 8.81 TWD 11.02 TWD 77
Owner Earnings 14.82 TWD 18.70 TWD 25.67 TWD 72
5Y Revenue Exit 7.22 TWD 8.53 TWD 10.44 TWD 68
5Y EBITDA Exit 7.51 TWD 9.05 TWD 11.08 TWD 71
10Y Revenue Exit 7.26 TWD 8.23 TWD 9.27 TWD 63
10Y EBITDA Exit 7.51 TWD 8.55 TWD 9.64 TWD 64
Dividend Discount
Gordon GGM 2.63 TWD 2.87 TWD 3.23 TWD 67
DDM Multi-Stage 2.63 TWD 3.26 TWD 4.10 TWD 65
Multiples
EV/EBITDA 8.03 TWD 9.30 TWD 10.58 TWD 64
EV/Revenue 7.23 TWD 8.53 TWD 9.83 TWD 52
Asset-Based
NCAV (Graham) 14.54 TWD 19.49 TWD 29.09 TWD 51
Growth DCF
Growth DCF 7.71 TWD 8.90 TWD 10.88 TWD 74
Rev-Margin DCF 7.22 TWD 8.61 TWD 10.33 TWD 68

Open the full fair value analysis →

Notify me when 6615 reaches fair value

Put 6615 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 49 · Market factors (momentum, volatility) 55

Profitability 17
Margins and returns on capital today
Quality Growth 11
Are margins and returns improving?
Cashflow 23
Earnings quality: real cash, not paper profit
Fin. Strength 85
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 83
Calm price path (market factor)
Momentum 39
Price trend over the last 3–12 months (market factor)
52W Momentum 50
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.9% (2021) → −8.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+36.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +34.1% a year for the price.

6615 screens 267% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Sofiva Genomics Co.,Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −73% · Bottom 25%
Profitability
Return on equity (TTM) 2% · Above median
Return on assets −2% · Below median
Net margin (TTM) 4% · Above median
Operating margin (TTM) −2% · Below median
Growth and dividend
Revenue growth −4% · Below median
Dividend yield (TTM) 0.9% · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 51.5× · Pricier than median
P/B 1.17× · Cheaper than median
P/S (TTM) 1.94× · Cheaper than median
P/FCF 3.2× · Cheaper than median
EV/EBITDA 86.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)9 · sector 8
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)17 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $678.39 $686.04 +1%
Danaher Corporation DHR $223.77 $209.18 −7%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sofiva Genomics Co.,Ltd. · Fair Value
9.26 TWD −267%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sofiva Genomics Co.,Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6615

Frequently asked questions

Is Sofiva Genomics Co.,Ltd. (6615) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 9.26 TWD versus a price of 34.00 TWD, about −73% upside (overvalued).
What is the fair value of 6615?
Our model-based fair value for Sofiva Genomics Co.,Ltd. is 9.26 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 34.00 TWD.
What is the quality score of 6615?
Sofiva Genomics Co.,Ltd. has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sofiva Genomics Co.,Ltd. (6615)?
Our model-based price target is the fair value of 9.26 TWD (as of Sep 24, 2026) from 13 valuation models. Cautious scenario 7.91 TWD, optimistic scenario 10.58 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Sofiva Genomics Co.,Ltd. stock forecast for 2026?
Our models put fair value at 9.26 TWD, about −73% upside versus a price of 34.00 TWD (overvalued). Cautious scenario 7.91 TWD, optimistic scenario 10.58 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Sofiva Genomics Co.,Ltd. (6615)?
Sofiva Genomics Co.,Ltd. reported trailing-twelve-month revenue of about 379M TWD (latest available figure, as of Sep 24, 2026).
Does Sofiva Genomics Co.,Ltd. pay a dividend?
Sofiva Genomics Co.,Ltd. currently shows a dividend yield of about 0.87% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Sofiva Genomics Co.,Ltd. (6615)?
For today's price to be fair in a discounted-cash-flow model, Sofiva Genomics Co.,Ltd. would have to grow free cash flow by +36.2 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -6.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 6615 use?
Our models discount Sofiva Genomics Co.,Ltd. at 9.0 %: a base by market capitalisation (nano), damped by beta 0.21, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sofiva Genomics Co.,Ltd. that is +36.2 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Sofiva Genomics Co.,Ltd. (6615) delivered so far?
Over the past 4 years revenue at Sofiva Genomics Co.,Ltd. grew -6.7 % a year. The price currently implies +36.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sofiva Genomics Co.,Ltd. (6615) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Sofiva Genomics Co.,Ltd. (+36.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sofiva Genomics Co.,Ltd. (6615)?
The free-cash-flow yield on the price is 0.98 %: that much free cash flow Sofiva Genomics Co.,Ltd. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sofiva Genomics Co.,Ltd. (6615)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sofiva Genomics Co.,Ltd. it is 9.26 TWD per share (as of Sep 24, 2026), against a price of 34.00 TWD. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Sofiva Genomics Co.,Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6615 trades above its calculated fair value: price 34.00 TWD, fair value 9.26 TWD, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6615?
No. The price is what the market pays today (34.00 TWD); the fair value is what the company's own numbers justify (9.26 TWD). For Sofiva Genomics Co.,Ltd. the two are 24.74 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Sofiva Genomics Co.,Ltd. worth?
The market values Sofiva Genomics Co.,Ltd. at about 734M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 34.00 TWD; our models calculate a fair value of 9.26 TWD per share.
What do the bullish and bearish scenarios say about 6615?
Our models span a range for Sofiva Genomics Co.,Ltd.: cautious scenario 7.91 TWD, base 9.26 TWD, optimistic 10.58 TWD per share (as of Sep 24, 2026, price 34.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6615?
Sofiva Genomics Co.,Ltd. trades at a price-to-earnings ratio of 51.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9.26 TWD is built from several models across several years. Other multiples: P/B 1.2, P/S 1.9, EV/EBITDA 86.1.
How solid is the balance sheet of Sofiva Genomics Co.,Ltd. (6615)?
Balance-sheet figures for Sofiva Genomics Co.,Ltd. (as of Sep 24, 2026): return on equity 2.3%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 6615 from its 52-week high?
Sofiva Genomics Co.,Ltd. trades at 34.00 TWD, about 10% below its 52-week high of 37.70 TWD and 16% above the low of 29.20 TWD (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 9.26 TWD is for.
Which stocks are comparable to Sofiva Genomics Co.,Ltd.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sofiva Genomics Co.,Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 34.00 TWD, calculated fair value 9.26 TWD (−73%), Quality Score 49/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6615 calculated?
We run Sofiva Genomics Co.,Ltd. through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9.26 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Sofiva Genomics Co.,Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sofiva Genomics Co.,Ltd. (6615)?
The closing price on Sep 23, 2026 was 34.00 TWD. Our model-based fair value is 9.26 TWD, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sofiva Genomics Co.,Ltd. right now?
The price sits above even our optimistic bull case (10.58 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Sofiva Genomics Co.,Ltd.

How large is the market capitalisation of Sofiva Genomics Co.,Ltd. (6615)?
The market capitalisation of Sofiva Genomics Co.,Ltd. is 734M TWD (≈ $23.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sofiva Genomics Co.,Ltd. (6615)?
The price-to-sales ratio of Sofiva Genomics Co.,Ltd. is 1.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sofiva Genomics Co.,Ltd. (6615)?
Earnings per share at Sofiva Genomics Co.,Ltd. are 0.6600 TWD (price ÷ EPS = P/E 51.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sofiva Genomics Co.,Ltd. (6615)?
The dividend yield of Sofiva Genomics Co.,Ltd. is 0.9% (payout 44.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sofiva Genomics Co.,Ltd. (6615)?
The net margin of Sofiva Genomics Co.,Ltd. is −2.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sofiva Genomics Co.,Ltd. (6615)?
The return on equity (ROE) of Sofiva Genomics Co.,Ltd. is 2.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sofiva Genomics Co.,Ltd. (6615)?
On an EBIT basis the return on assets of Sofiva Genomics Co.,Ltd. is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sofiva Genomics Co.,Ltd. (6615)?
The operating margin of Sofiva Genomics Co.,Ltd. is −2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sofiva Genomics Co.,Ltd. (6615)?
Revenue at Sofiva Genomics Co.,Ltd. is growing −3.6% versus a year earlier (3y avg −8.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed

Watch Sofiva Genomics Co.,Ltd. in the live analysis

One click puts Sofiva Genomics Co.,Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.